The CDIATM Fentanyl Colloidal Gold Test Cassette (Urine) is a lateral flow chromatographic immunoassay for the detection of fentanyl and its metabolites in human urine.
Fentanyl antigen is coated on the test region of the nitrocellulose membrane of the strips, and fentanyl antibody is labeled with colloid gold. During a test, the colloid gold labeled antibody coated in the strip move forward along the membrane, and a red line will show up when the antibody gathers with the antigen in the test line; if fentanyl in the sample is over the detection limit, line T is blank; on the other wise, if fentanyl in the sample is less than the detection limit, line T is red.
Fentanyl is an extremely fast-acting synthetic narcotic analgesic, of high potency(approximately 100 to 200 times that of morphine) and short duration of action. Pharmaceutical fentanyl has been available since 1963 as an anaesthetic supplement, and is available as a citrate salt for I.V or I.M injection. Transdermal patches are also available for management of chronic pain or for breakthrough cancer pain. Due to the lipophilicity of the drug, fentanyl rapidly crosses the blood-brain barrier, producing fast and pronounced CNS effect, such as a heightened euphoria and respiratory depression, and possible toxic effects which include muscle rigidity, seizures, coma, and hypotension. Fentanyl also has similar tolerance and physical dependence properties to those of morphine. The CDIATM Fentanyl Colloidal Gold Test Cassette (Urine) is a rapid urine-screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of fentanyl in urine. The CDIATM Fentanyl Colloidal Gold Test Cassette (Urine) yields a positive result when the fentanyl in urine exceeds 300/200 ng/mL.